FLT3 and acute myeloid leukemia: Concomitant exposure of FLT3-ITD AML cell lines to quizartinib (FLT3 inhibitor) and CB-839 potently decreased viability and enhanced the overall survival of immune-deficient mice engrafted with AML patient-derived xenografts implying the dependence of AML cells on glutamine metabolism for drug resistance (146).